The online version of this article (https://doi.org/10.1007/s12325-018-0753-6) contains supplementary material, which is available to authorized users.
To view enhanced digital content for this article go to https://doi.org/10.6084/m9.figshare.6797690.
The effectiveness of inhaled therapies can be influenced by many factors, including the type of inhaler, which may have clinical implications. We report a real-world, multicenter, open-label, non-randomized, non-interventional study conducted by 200 pulmonologists across 200 centers in Hungary. The effectiveness of budesonide/formoterol inhalation therapy in daily clinical practice, delivered via the Bufomix Easyhaler®, was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO).
Effectiveness was assessed after 12 weeks of treatment by spirometry, the Asthma Control Test, mini-Asthma Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council dyspnea scale. Patient satisfaction with the Bufomix Easyhaler® and physicians’ assessments (ease of use and time taken to learn the technique) were also assessed.
A total of 1498 patients with obstructive airway disease were evaluated (asthma: n = 621; COPD: n = 778; ACO: n = 99), of whom 455 (30.4%) were newly diagnosed inhaler-naïve patients and 1043 (69.6%) were switching from other inhalers. Significant improvements in lung function, disease control and health-related quality of life measures (all p ≤ 0.002) were reported after 12 weeks of Bufomix Easyhaler® use. Improvements were observed in both inhaler-naïve patients and those who switched to a Bufomix Easyhaler® from other devices. After switching, 72.4% of patients regarded the Bufomix Easyhaler® as ‘very good’ and > 90.0% of physicians described the Bufomix Easyhaler® as easy to teach; 73.8% and 98.9% of patients learned the technique within 5 and 10 min of teaching, respectively.
Twelve weeks’ treatment with the Bufomix Easyhaler® resulted in significant improvements in disease control and quality of life. The Bufomix Easyhaler® was considered easy to use, and most patients were satisfied with the inhaler. Results confirm the real-world effectiveness of the Bufomix Easyhaler® in the treatment of adult outpatients with obstructive airway disease.
Orion Corp., Orion Pharma.
Supplementary material 1 (DOCX 1085 kb)12325_2018_753_MOESM1_ESM.docx
World Health Organisation. Global Health Observatory (GHO) Data. 2016. http://www.who.int/gho/ncd/mortality_morbidity/en/ Accessed 12 April 2018.
Global Initiative for Asthma (GINA), National Heart Lung and Blood Institute, National Institutes of Health. GINA report Global strategy for asthma management and prevention. http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed 12th April 2018.
Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D. Author correction: the impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting beta2-agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim Care Respir Med. 2017;27(1):65. CrossRefPubMedPubMedCentral
Global Asthma Network. The global asthma Report. 2014. http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf. Accessed 12 April 2018.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. http://goldcopd.org/. Accessed 12th April 2018.
Ferguson GT, Tashkin DP, Skärby T, et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med. 2017;132:31–41. CrossRefPubMed
Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clinical implications of differences in effectiveness. BioDrugs. 1996;6:273–99.
Orion Pharma. Bufomix Easyhaler ® SPC. http://www.medicines.ie/medicine/16038/SPC/Bufomix+Easyhaler®+320+micrograms+9+micrograms/ Accessed 12th April 2018.
European Medicines Compendium. Orion pharma (UK) limited. Summary of product characteristics for fobumix easyhaler 160/4.5 inhalation powder. https://www.medicines.org.uk/emc/product/8706/smpc/ Accessed 22 June 2016.
European Medicines Compendium. Orion pharma (UK) limited. Summary of product characteristics for fobumix easyhaler 320 micrograms/9 micrograms, inhalation powder. https://www.medicines.org.uk/emc/product/8438/smpc/ Accessed 22 June 2016.
Rytilä PH, Syk J, Vinge I, Sörberg M. Switch from Symbicort Turbuhaler to Budesonide/Formoterol Easyhaler; a real-life prospective study in asthma patients. Orion Pharma. Data on file 2018. Abstract accepted for presentation at the European Respiratory Society Meeting, to be published in a supplement of the European Respiratory Journal, September 2018.
- Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II